Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.Financial_Report.xls
10-K - ANNUAL REPORT - Cannabics Pharmaceuticals Inc.amcm_10k31aug12.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Cannabics Pharmaceuticals Inc.R10.htm
EX-32.1 - CERTIFICATION - Cannabics Pharmaceuticals Inc.amcm_10k31aug12ex32.htm
EX-31.1 - CERTIFICATION - Cannabics Pharmaceuticals Inc.amcm_10k31aug12ex31.htm
v2.4.0.6
Statements of Operations (USD $)
12 Months Ended 96 Months Ended
Aug. 31, 2012
Aug. 31, 2011
Aug. 31, 2012
EXPENSES      
Amortization       $ 2,153
Bad debt expense    102,228 102,228
Business development       105,227
Business acquisition costs (18,750) 18,750   
General and administrative expenses 45    11,175
Interest expenses and bank charges 13    1,848
Leases       3,547
Professional fees 19,849 21,318 110,828
Transfer agent 495 2,114 9,994
Write-off of oil & gas property (note 5)       97,635
Operating loss 1,652 144,410 444,635
Other income and expenses      
Gain on debt settlement    (31,787) (31,787)
Foreign exchange (gain)/loss    (5,313) (1,503)
Net loss and comprehensive loss for the period $ (1,652) $ (107,310) $ (411,345)
Basic and diluted loss per share $ 0.00 $ (0.16)  
Weighted average number of common shares outstanding      
- basic and diluted   680,202 680,202